Hyperlipidemia

ATLANTA — Younger women with a diagnosis of anxiety or depression are at markedly higher risk for developing conditions that increase CVD risk, such as hypertension, hyperlipidemia and diabetes, researchers reported.

PCSK9 inhibitors are rejected by insurance providers at a higher rate compared with other guideline-indicated cardiometabolic drugs despite expanded labeling and reduced manufacturer cost, researchers reported.

Heart disease continues to be the leading cause of death and disability in the U.S. and worldwide. Atherosclerotic CVD, which is caused by plaque buildup in arterial walls, contributes to multiple life-threatening conditions.

BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.

PHILADELPHIA — In the CLEAR Outcomes cohort of patients with statin intolerance, inflammation predicted risk for CV events and death more strongly than cholesterol, researchers reported at the American Heart Association Scientific Sessions.

PHILADELPHIA — Recaticimab, a novel anti-PCSK9 drug, conferred significant LDL reductions at 48 weeks in a cohort of patients with mixed hyperlipidemias already on statin therapy, a speaker reported.

VANCOUVER, British Columbia — Despite recent changes in nomenclature for metabolic dysfunction-associated steatotic liver disease, an expert here noted that clinical pathways largely remain the same and require reinforcing.

The fully monoclonal angiopoietin-like 3 antibody evinacumab conferred sustained, long-term reductions in LDL and other atherogenic lipoproteins among patients with refractory hyperlipidemia, researchers reported.

As allies in delivering evidence-based data, breaking news, professional resources and medical education to practicing clinicians, Healio and CMHC are proud to partner for the much-anticipated Cardiometabolic Health Congress.

Patients who underwent bariatric surgery for morbid obesity had a “substantial and long-lasting reduction” of lipid-lowering and antidiabetic medication use compared with patients who did not undergo surgery.